IN2012DN03348A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03348A
IN2012DN03348A IN3348DEN2012A IN2012DN03348A IN 2012DN03348 A IN2012DN03348 A IN 2012DN03348A IN 3348DEN2012 A IN3348DEN2012 A IN 3348DEN2012A IN 2012DN03348 A IN2012DN03348 A IN 2012DN03348A
Authority
IN
India
Prior art keywords
monoclonal antibodies
methods
progastrin
compositions
present disclosure
Prior art date
Application number
Inventor
Pannequin Julie
Boudier Laure
Joubert Dominique
Hollande Frederic
Original Assignee
Biorealites
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43086711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN03348(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biorealites, Inst Nat Sante Rech Med, Centre Nat Rech Scient filed Critical Biorealites
Publication of IN2012DN03348A publication Critical patent/IN2012DN03348A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
IN3348DEN2012 2009-10-16 2010-10-15 IN2012DN03348A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25262509P 2009-10-16 2009-10-16
PCT/EP2010/006329 WO2011045080A2 (en) 2009-10-16 2010-10-15 Monoclonal antibodies to progastrin and their uses

Publications (1)

Publication Number Publication Date
IN2012DN03348A true IN2012DN03348A (en) 2015-10-23

Family

ID=43086711

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3348DEN2012 IN2012DN03348A (en) 2009-10-16 2010-10-15

Country Status (41)

Country Link
US (7) US9611320B2 (en)
EP (2) EP2488551B1 (en)
JP (3) JP5985987B2 (en)
KR (2) KR101640520B1 (en)
CN (2) CN104628857A (en)
AP (1) AP2012006262A0 (en)
AR (1) AR078659A1 (en)
AU (1) AU2010306119A1 (en)
BR (1) BR112012008818B1 (en)
CA (1) CA2777691C (en)
CL (1) CL2012000914A1 (en)
CR (1) CR20120184A (en)
CU (1) CU24196B1 (en)
CY (1) CY1120913T1 (en)
DK (1) DK2488551T3 (en)
EA (2) EA201791876A1 (en)
EC (1) ECSP12011796A (en)
ES (2) ES2973217T3 (en)
GE (1) GEP201706604B (en)
GT (1) GT201200114A (en)
HK (1) HK1178183A1 (en)
HN (1) HN2012000708A (en)
HR (1) HRP20181645T1 (en)
IL (2) IL219019B (en)
IN (1) IN2012DN03348A (en)
LT (1) LT2488551T (en)
MA (1) MA33747B1 (en)
MX (1) MX351635B (en)
NI (1) NI201200054A (en)
NZ (2) NZ701709A (en)
PE (1) PE20121649A1 (en)
PL (2) PL3421493T3 (en)
PT (1) PT2488551T (en)
RS (1) RS57966B1 (en)
SG (1) SG10201704933PA (en)
SI (1) SI2488551T1 (en)
TN (1) TN2012000159A1 (en)
TW (1) TWI537002B (en)
UA (1) UA106771C2 (en)
WO (1) WO2011045080A2 (en)
ZA (1) ZA201202642B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7854932B2 (en) 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
US8136651B2 (en) * 2007-12-14 2012-03-20 The Procter & Gamble Company Method and apparatus for orienting articles
AR078659A1 (en) * 2009-10-16 2011-11-23 Biorealites S A MONOCLONAL ANTIBODIES AGAINST HUMAN PROGASTRINE AND ITS USES
US8900588B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
US8900817B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
JP5829672B2 (en) * 2010-03-24 2015-12-09 レ ラボラトワール セルヴィエ Prevention of colorectal and gastrointestinal cancer
EA028515B1 (en) * 2010-07-26 2017-11-30 Ле Лаборатуар Сервье Methods and compositions for liver cancer therapy
US8785603B2 (en) 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
EP2715364A1 (en) 2011-06-01 2014-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the risk of developing a colonic neoplasia
WO2015003114A1 (en) * 2013-07-05 2015-01-08 University Of Washington Through Its Center For Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
US10023651B2 (en) 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
JP6740135B2 (en) * 2014-04-18 2020-08-12 ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク Humanized anti-TF-antigen antibody
WO2016066671A1 (en) 2014-10-29 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant cancers using progastrin inhibitors
AU2016324021A1 (en) * 2015-09-15 2018-04-12 The Scripps Research Institute Antibodies for generating anti-inflammatory macrophage and related uses
CN108780091A (en) * 2015-12-31 2018-11-09 普莱戈斯瑞恩癌症有限责任公司 Composition for detecting and treating oophoroma and method
AU2017204685B2 (en) * 2015-12-31 2022-10-13 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting and treating gastric cancer
MA43550A (en) * 2015-12-31 2018-11-07 Syncerus S A R L COMPOSITIONS AND METHODS FOR EVALUATING THE RISK OF DEVELOPING CANCER
WO2018178364A1 (en) * 2017-03-30 2018-10-04 Progastrine Et Cancers S.À R.L. Compositions and methods for treating lung cancer
EP3601347B1 (en) * 2017-03-30 2021-11-03 Progastrine et Cancers S.à r.l. Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
EP3720879B1 (en) * 2017-12-05 2022-05-11 Progastrine et Cancers S.à r.l. Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
TW201927343A (en) 2017-12-08 2019-07-16 瑞士商Ｅｃｓ生物識別系統有限公司 Radiolabeled progastrin in cancer diagnosis
TW201940881A (en) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 Combining progastrin detection with other cancer biomarkers in cancer diagnosis
WO2019166499A1 (en) * 2018-02-27 2019-09-06 Ecs-Progastrin Sa Progastrin as a biomarker for immunotherapy
TWI793238B (en) * 2018-12-27 2023-02-21 偉喬生醫股份有限公司 Method and kit of detecting gastrogenic protein in biological sample in vitro
CN115785273B (en) * 2021-09-10 2023-10-31 东莞市朋志生物科技有限公司 Antibody for resisting pepsinogen I and application thereof
CN116143920A (en) * 2022-12-30 2023-05-23 南京岚煜生物科技有限公司 Preparation method and application of monoclonal antibody of gastrin 17 and cell strain thereof
CN117567611B (en) * 2023-11-22 2024-05-14 艾维可生物科技有限公司 Monoclonal antibody against mature gastrin 17 and application thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
MX9204374A (en) 1991-07-25 1993-03-01 Idec Pharma Corp RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION.
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
EP2567974A3 (en) * 2004-09-22 2013-05-22 Cancer Advances, Inc., Monoclonal antibodies to progastrin
ES2727306T3 (en) * 2006-05-22 2019-10-15 Inst Nat Sante Rech Med Progastrin inhibitors in the treatment of colon cancer
US7854932B2 (en) 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
AR078659A1 (en) * 2009-10-16 2011-11-23 Biorealites S A MONOCLONAL ANTIBODIES AGAINST HUMAN PROGASTRINE AND ITS USES

Also Published As

Publication number Publication date
MX351635B (en) 2017-10-23
TN2012000159A1 (en) 2013-12-12
CY1120913T1 (en) 2019-12-11
WO2011045080A2 (en) 2011-04-21
GEP201706604B (en) 2017-01-25
IL254004B2 (en) 2023-06-01
CU20120060A7 (en) 2013-04-19
KR20120091221A (en) 2012-08-17
US11299542B2 (en) 2022-04-12
US10385125B2 (en) 2019-08-20
CU24196B1 (en) 2016-09-30
EP3421493B1 (en) 2024-01-17
MX2012004400A (en) 2012-06-27
NZ599971A (en) 2014-12-24
EA201791876A1 (en) 2018-01-31
PT2488551T (en) 2018-10-31
US20180022802A1 (en) 2018-01-25
EP2488551A2 (en) 2012-08-22
RS57966B1 (en) 2019-01-31
CL2012000914A1 (en) 2012-09-14
AU2010306119A1 (en) 2012-05-03
GT201200114A (en) 2014-08-11
WO2011045080A3 (en) 2011-07-07
KR20150082672A (en) 2015-07-15
CN102791735A (en) 2012-11-21
ES2973217T3 (en) 2024-06-19
EA029271B1 (en) 2018-03-30
CR20120184A (en) 2012-08-20
IL219019A0 (en) 2012-06-28
BR112012008818A2 (en) 2018-05-22
JP5985987B2 (en) 2016-09-06
CA2777691A1 (en) 2011-04-21
UA106771C2 (en) 2014-10-10
US10377821B2 (en) 2019-08-13
NI201200054A (en) 2012-08-20
PE20121649A1 (en) 2012-12-08
ZA201202642B (en) 2013-06-26
NZ701709A (en) 2016-06-24
US20170306011A1 (en) 2017-10-26
JP2017212992A (en) 2017-12-07
MA33747B1 (en) 2012-11-01
LT2488551T (en) 2018-10-25
KR101640520B1 (en) 2016-07-19
IL219019B (en) 2019-05-30
PL2488551T3 (en) 2019-01-31
JP2015145380A (en) 2015-08-13
EP3421493C0 (en) 2024-01-17
HN2012000708A (en) 2015-06-22
EP2488551B1 (en) 2018-07-25
ECSP12011796A (en) 2012-06-29
US20220195035A1 (en) 2022-06-23
US20110117086A1 (en) 2011-05-19
HK1178183A1 (en) 2013-09-06
EP3421493A1 (en) 2019-01-02
CA2777691C (en) 2018-02-27
DK2488551T3 (en) 2018-10-08
US20170174761A1 (en) 2017-06-22
US20170306012A1 (en) 2017-10-26
SG10201704933PA (en) 2017-07-28
US9611320B2 (en) 2017-04-04
PL3421493T3 (en) 2024-04-29
IL254004A0 (en) 2017-10-31
AR078659A1 (en) 2011-11-23
CN102791735B (en) 2016-05-18
HRP20181645T1 (en) 2018-12-14
CN104628857A (en) 2015-05-20
BR112012008818B1 (en) 2021-10-19
TWI537002B (en) 2016-06-11
JP6272793B2 (en) 2018-01-31
ES2690943T3 (en) 2018-11-23
US20200002413A1 (en) 2020-01-02
JP2013507138A (en) 2013-03-04
SI2488551T1 (en) 2019-01-31
US10385124B2 (en) 2019-08-20
AP2012006262A0 (en) 2012-06-30
EA201200597A1 (en) 2012-12-28
US10385126B2 (en) 2019-08-20
TW201119675A (en) 2011-06-16

Similar Documents

Publication Publication Date Title
IN2012DN03348A (en)
MX2020010639A (en) Humanized antibodies to liv-1 and use of same to treat cancer.
JO3097B1 (en) c-Met Antibodies
PH12014502419A1 (en) Specific binding proteins and uses thereof
NZ599737A (en) Il-17a antagonists
MX2019004193A (en) Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer.
WO2009126934A3 (en) Detection and tratment of pancreatic, ovarian and other cancers
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
WO2010017515A3 (en) Breast cancer specific markers and methods of use
EA201500219A1 (en) ANTIBODY AGAINST TROP-2 PERSON HAS ANTI-TUMOR ACTIVITY IN VIVO
MX2012001782A (en) Combination therapy of an afucosylated cd20 antibody with bendamustine.
UA114277C2 (en) Anti-angiogenesis therfpy for the treatment of ovarian cancer
NZ584787A (en) Inhibition of angiogenesis with a Bv8 antagonist
MX352373B (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof.
MX347463B (en) Combination therapy of an afucosylated cd20 antibody with an anti-vegf antibody.
WO2013149219A3 (en) Fully human antibodies that bind to vegfr2
MX362497B (en) Methods for treatment of gastric cancer.
TH133902A (en) Monoclonal Antibody for Progastrin and Uses of Monoclonal Antibody
TH133902B (en) Monoclonal Antibody for Progastrin and Its Application of Monoclonal Antibody
TR201905240T4 (en) Humanized antibodies to LIV-1 and their use in the treatment of cancer.
UA104739C2 (en) c-MET ANTIBODIES